首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis, crystal structure and initial biological evaluation of the new enantiomerically pure chiral palladium(II) complex trans-bis(endo-(1R)-1,7,7-trimethylbicyclo(2.2.1)-heptan-2-amino)palladium (II)dichloride.
【24h】

Synthesis, crystal structure and initial biological evaluation of the new enantiomerically pure chiral palladium(II) complex trans-bis(endo-(1R)-1,7,7-trimethylbicyclo(2.2.1)-heptan-2-amino)palladium (II)dichloride.

机译:新型对映体纯的手性钯(II)配合物反式双(内-(1R)-1,7,7-三甲基双环(2.2.1)-庚-2-氨基)钯(的合成,晶体结构和初步生物学评估II)二氯化物。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The palladium(II) complex trans-bis[(R)-(+)-bornylamino]palladium(II) dichloride was synthesised and characterised. The solid state structure of the complex was determined by X-ray structure analysis. The compound crystallises in the monoclinic space group P2(1) with a=12.383(2), b=23.689(5), c=12.769(3) A, beta=93.25(3) degrees, and V=3739.6(13) A(3). The complex was tested for its cytotoxicity against L(929), K(562) and HeLa cell lines using the MTT assay technique. It is also tested for its anticomplementary activity using a test that detects complement proteins inhibition. These activities were compared with those of the reference standards, cisplatin, carboplatin and oxaliplatin. The significance of these results is given and discussed.
机译:合成并表征了钯(II)配合物反式双[[(R)-(+)-冰片烷基氨基]钯(II))。通过X射线结构分析确定配合物的固态结构。该化合物在a = 12.383(2),b = 23.689(5),c = 12.769(3)A,β= 93.25(3)度和V = 3739.6(13)的单斜空间群P2(1)中结晶A(3)。使用MTT分析技术测试了该复合物对L(929),K(562)和HeLa细胞系的细胞毒性。还使用检测补体蛋白抑制的测试来测试其抗补体活性。将这些活性与参考标准的顺铂,卡铂和奥沙利铂进行了比较。给出并讨论了这些结果的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号